Cargando…

Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast

Squamous cell carcinoma (SCC) of the breast is a rare malignancy that usually has a triple-negative phenotype and poor clinical outcomes. Because HER2-positive SCC of the breast is extremely rare, its clinicopathologic features are understudied, and the effects of neoadjuvant chemotherapy including...

Descripción completa

Detalles Bibliográficos
Autores principales:	Usui, Yuki, Matsunuma, Ryoichi, Yamaguchi, Kei, Hayami, Ryosuke, Muramatsu, Aya, Suzuki, Makoto, Tsuneizumi, Michiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613576/ https://www.ncbi.nlm.nih.gov/pubmed/34899248 http://dx.doi.org/10.1159/000519746

Ejemplares similares

Fertility preservation before neoadjuvant chemotherapy in a premenopausal breast cancer patient: a case report
por: Kobayashi, Arika, et al.
Publicado: (2019)

Large Breast Tumor Ulceration and Quality of Life in an 80-Year-Old Woman
por: Yamaguchi, Kei, et al.
Publicado: (2021)

Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome
por: Tsuneizumi, Michiko, et al.
Publicado: (2022)

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy
por: Kumeta, Toko, et al.
Publicado: (2019)

Acquired Treatment Resistance in a Patient with Metastatic PD-L1-Positive Breast Cancer and Germline BRCA1 Mutation
por: Kumeta, Toko, et al.
Publicado: (2023)

Concurrent Bowen's Disease of the Nipple and Breast Cancer
por: Yamaguchi, Kei, et al.
Publicado: (2020)

Enrichment of Immune-Related Genes in Aggressive Primary Breast Angiosarcoma: A Case Report
por: Matsunuma, Ryoichi, et al.
Publicado: (2023)

A Case of Metaplastic Squamous Cell Carcinoma of the Breast that Showed a Pathological Complete Response After Neoadjuvant Chemotherapy with Weekly Paclitaxel
por: Noro, Aya, et al.
Publicado: (2022)

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
por: Ilie, Silvia Mihaela, et al.
Publicado: (2023)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
por: Cedeño, Heidy, et al.
Publicado: (2007)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
por: Piras, Marta, et al.
Publicado: (2021)

Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer
por: An, Selena J., et al.
Publicado: (2022)

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
por: Mizuno, Takaaki, et al.
Publicado: (2020)

Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response
por: Dong, Jing-Min, et al.
Publicado: (2018)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
por: Tateishi, Kaho, et al.
Publicado: (2023)

Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients
por: Mazo, Claudia, et al.
Publicado: (2020)

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy
por: Lee, Eun-Gyeong, et al.
Publicado: (2023)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer
por: Zhang, Lin, et al.
Publicado: (2020)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
por: Phung, Huyen Thi, et al.
Publicado: (2020)

PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
por: Shi, Qiyun, et al.
Publicado: (2022)

Noninvasive imaging signatures of HER2 and HR using ADC in invasive breast cancer: repeatability, reproducibility, and association with pathological complete response to neoadjuvant chemotherapy
por: Teng, Xinzhi, et al.
Publicado: (2023)

Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features
por: Park, Jiwoo, et al.
Publicado: (2023)

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
por: Huang, Ren-Wen, et al.
Publicado: (2014)

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Baron, Paul, et al.
Publicado: (2015)

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
por: Sasanpour, Pegah, et al.
Publicado: (2018)

Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
por: Müller, Carolin, et al.
Publicado: (2021)

Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia
por: Rodríguez, Mauricio, et al.
Publicado: (2023)

PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS
por: ANDREOLLO, Nelson Adami, et al.
Publicado: (2018)

Pathological complete response after neoadjuvant chemotherapy for rectal cancer with synchronous multiple liver metastases: a report of an unusual case
por: Arata, Ryosuke, et al.
Publicado: (2016)

Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study
por: Tang, Lingfeng, et al.
Publicado: (2022)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_342n3haidqopj57dp5fp0fpqao